At the end of January, Farmak successfully passed a scheduled re-certification inspection conducted by the Polish Chief Pharmaceutical Inspectorate (GIF). The inspection assessed compliance with the requirements of EU Good Manufacturing Practice (EU GMP).
The inspection covered facilities across five manufacturing workshops producing medicinal products in both sterile and non-sterile dosage forms and across various therapeutic areas — including injectable and infusion medicines, as well as tablets, capsules, sprays, and others.
This was a large-scale and comprehensive assessment of the quality, safety, and consistency of manufacturing processes. As a result of the inspection, Farmak fully confirmed its compliance with EU GMP requirements.
Passing the inspection by the Polish regulatory authority is a critically important prerequisite for access to European Union markets and serves as confirmation that the Ukrainian manufacturer operates in accordance with the same standards as leading EU pharmaceutical companies.
Farmak exports medicinal products to 60 countries worldwide and systematically undergoes inspections by international regulatory authorities. In particular, in 2024 the company successfully passed an inspection by HALMED (Croatia), and in 2025 — by China’s regulatory authority, the NMPA.
The Farmak Group is a global pharmaceutical business founded in Ukraine in 1925. It operates manufacturing facilities in Ukraine and Spain and includes 11 companies and international representative offices in Poland, the Czech Republic, Slovakia, the United Kingdom, the UAE, Vietnam, Switzerland, Kazakhstan, Uzbekistan, Kyrgyzstan, and Moldova.
